Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation
ObjectivesTo explore the benefit and safety of transarterial chemoembolization (TACE) in combination with sorafenib in patients with recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT).MethodsIn this multi-center retrospective study, 106 patients with recurrent HCC...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1101351/full |
| _version_ | 1797953866336043008 |
|---|---|
| author | Xia Zhang Lirong Cai Jian Fang Fengsui Chen Fan Pan Kun Zhang Qian Huang Yuju Huang Dongliang Li Lizhi Lv Man Chen Ruiying Yan Yanhua Lai Yonghai Peng Zhixian Wu |
| author_facet | Xia Zhang Lirong Cai Jian Fang Fengsui Chen Fan Pan Kun Zhang Qian Huang Yuju Huang Dongliang Li Lizhi Lv Man Chen Ruiying Yan Yanhua Lai Yonghai Peng Zhixian Wu |
| author_sort | Xia Zhang |
| collection | DOAJ |
| description | ObjectivesTo explore the benefit and safety of transarterial chemoembolization (TACE) in combination with sorafenib in patients with recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT).MethodsIn this multi-center retrospective study, 106 patients with recurrent HCC after OLT were included. Fifty-two patients were treated with TACE plus sorafenib (TS group) and 54 were treated with TACE alone (TC group). Primary and secondary endpoints including overall survival (OS) and progression-free survival (PFS), and safety were assessed.ResultsThe median OS (17 vs 10 months, P=0.035) and PFS (12 vs 6 months, P=0.004) in the TS group were longer than those in the TC group. On multivariate analysis, BCLC stage (HR [hazard ratio]=0.73 [95% CI, 0.27–0.99], P=0.036) and sorafenib medication (HR=2.26 [95% CI, 1.35–3.69], P=0.01) were identified as independent prognostic risk factors for OS. No severe adverse events related to sorafenib were noted in the TS group. Four patients discontinued sorafenib due to intolerance.ConclusionTACE in combination with sorafenib is a feasible regimen to improve the survival with mild toxicity in patients with recurrent HCC after OLT. |
| first_indexed | 2024-04-10T23:08:47Z |
| format | Article |
| id | doaj.art-4a1ccab9394148fabb58b7906153b75f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T23:08:47Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4a1ccab9394148fabb58b7906153b75f2023-01-13T06:40:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011210.3389/fonc.2022.11013511101351Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantationXia Zhang0Lirong Cai1Jian Fang2Fengsui Chen3Fan Pan4Kun Zhang5Qian Huang6Yuju Huang7Dongliang Li8Lizhi Lv9Man Chen10Ruiying Yan11Yanhua Lai12Yonghai Peng13Zhixian Wu14Department of Hepatobiliary Disease, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Disease, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Disease, The Third People’s Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, ChinaDepartment of Hepatobiliary Disease, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Surgery, Xiang’an Hospital, Xiamen University, Xiamen, ChinaDepartment of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Disease, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Disease, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Disease, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Hepatobiliary Disease, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaDepartment of Transplantation, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, ChinaDepartment of Oncology, the 900th Hospital of Joint Logistics Support Force, Fujian Medica University, Fuzhou, ChinaDepartment of Hepatobiliary Disease, the 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, ChinaObjectivesTo explore the benefit and safety of transarterial chemoembolization (TACE) in combination with sorafenib in patients with recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT).MethodsIn this multi-center retrospective study, 106 patients with recurrent HCC after OLT were included. Fifty-two patients were treated with TACE plus sorafenib (TS group) and 54 were treated with TACE alone (TC group). Primary and secondary endpoints including overall survival (OS) and progression-free survival (PFS), and safety were assessed.ResultsThe median OS (17 vs 10 months, P=0.035) and PFS (12 vs 6 months, P=0.004) in the TS group were longer than those in the TC group. On multivariate analysis, BCLC stage (HR [hazard ratio]=0.73 [95% CI, 0.27–0.99], P=0.036) and sorafenib medication (HR=2.26 [95% CI, 1.35–3.69], P=0.01) were identified as independent prognostic risk factors for OS. No severe adverse events related to sorafenib were noted in the TS group. Four patients discontinued sorafenib due to intolerance.ConclusionTACE in combination with sorafenib is a feasible regimen to improve the survival with mild toxicity in patients with recurrent HCC after OLT.https://www.frontiersin.org/articles/10.3389/fonc.2022.1101351/fullhepatocellular carcinomasorafenibtransarterial chemoembolizationliver transplantationoverall survival |
| spellingShingle | Xia Zhang Lirong Cai Jian Fang Fengsui Chen Fan Pan Kun Zhang Qian Huang Yuju Huang Dongliang Li Lizhi Lv Man Chen Ruiying Yan Yanhua Lai Yonghai Peng Zhixian Wu Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation Frontiers in Oncology hepatocellular carcinoma sorafenib transarterial chemoembolization liver transplantation overall survival |
| title | Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation |
| title_full | Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation |
| title_fullStr | Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation |
| title_full_unstemmed | Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation |
| title_short | Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation |
| title_sort | efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation |
| topic | hepatocellular carcinoma sorafenib transarterial chemoembolization liver transplantation overall survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1101351/full |
| work_keys_str_mv | AT xiazhang efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT lirongcai efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT jianfang efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT fengsuichen efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT fanpan efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT kunzhang efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT qianhuang efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT yujuhuang efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT dongliangli efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT lizhilv efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT manchen efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT ruiyingyan efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT yanhualai efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT yonghaipeng efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation AT zhixianwu efficacyandsafetyoftransarterialchemoembolizationplussorafenibinpatientswithrecurrenthepatocellularcarcinomaafterlivertransplantation |